molsidomine has been researched along with Cruveilhier-Baumgarten Syndrome in 18 studies
Molsidomine: A morpholinyl sydnone imine ethyl ester, having a nitrogen in place of the keto oxygen. It acts as NITRIC OXIDE DONORS and is a vasodilator that has been used in ANGINA PECTORIS.
molsidomine : A member of the class of oxadiazoles that is 1,2,3-oxadiazole substituted by morpholin-4-yl and (ethoxycarbonyl)azanidyl groups at positions 3 and 5, respectively. It is used as a vasodilator drug for the treatment of myocardial ischemic syndrome and congestive heart failure.
Cruveilhier-Baumgarten Syndrome: Liver cirrhosis with intrahepatic portal obstruction, HYPERTENSION, and patent UMBILICAL VEINS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "2 [34-67] years) with cirrhosis of the liver of various aetiologies to determine whether molsidomine, which selectively reduces pre-load with-out the development of tolerance, effects portal and cardiac haemodynamics in liver cirrhosis and portal hypertension." | 7.68 | [The effect of molsidomine on portal and cardiac hemodynamics in liver cirrhosis]. ( Barmeyer, J; Hüppe, D; Jäger, D; May, B; Tromm, A; Tunn, S, 1991) |
| " The aim of the present study was to assess the hemodynamic effects of molsidomine, an antianginal agent, which does not induce tolerance and has little effect on arterial pressure in patients with normal liver, in 13 patients with alcoholic cirrhosis." | 7.68 | Hemodynamic evaluation of molsidomine: a vasodilator with antianginal properties in patients with alcoholic cirrhosis. ( Calés, P; Combis, JM; Desmorat, H; Monnin, JL; Pascal, JP; Vinel, JP, 1990) |
| "Patients suffering from congestive heart failure combined with gastrointestinal congestion often present irregular resorption and metabolism of orally applicated cardiovascular drugs." | 6.67 | [Molsidomine in chronic heart failure with liver congestion--oral or intravenous therapy?]. ( Grosse-Heitmeyer, W; Huber, T; Ostrowski, J, 1993) |
| "2 [34-67] years) with cirrhosis of the liver of various aetiologies to determine whether molsidomine, which selectively reduces pre-load with-out the development of tolerance, effects portal and cardiac haemodynamics in liver cirrhosis and portal hypertension." | 3.68 | [The effect of molsidomine on portal and cardiac hemodynamics in liver cirrhosis]. ( Barmeyer, J; Hüppe, D; Jäger, D; May, B; Tromm, A; Tunn, S, 1991) |
| " The aim of the present study was to assess the hemodynamic effects of molsidomine, an antianginal agent, which does not induce tolerance and has little effect on arterial pressure in patients with normal liver, in 13 patients with alcoholic cirrhosis." | 3.68 | Hemodynamic evaluation of molsidomine: a vasodilator with antianginal properties in patients with alcoholic cirrhosis. ( Calés, P; Combis, JM; Desmorat, H; Monnin, JL; Pascal, JP; Vinel, JP, 1990) |
| "Patients suffering from congestive heart failure combined with gastrointestinal congestion often present irregular resorption and metabolism of orally applicated cardiovascular drugs." | 2.67 | [Molsidomine in chronic heart failure with liver congestion--oral or intravenous therapy?]. ( Grosse-Heitmeyer, W; Huber, T; Ostrowski, J, 1993) |
| "When molsidomine was added, TAV was further decreased (-17." | 2.67 | [Evaluation of the effects of molsidomine and propranolol-molsidomine combination on portal hemodynamics by pulsed Doppler ultrasound]. ( Blanc, F; Bruel, JM; Ciurana, AJ; Le Quellec, A; Michel, H; Monnin, JL; Pascal, JP; Taourel, P; Vinel, JP, 1992) |
| "The pharmacologic treatment of portal hypertension should be able to stop as well as to prevent variceal hemorrhage." | 2.38 | Pharmacologic treatment of portal hypertension. ( Groszmann, RJ; Rodríguez-Pérez, F, 1992) |
| "Although pharmacologic treatment of portal hypertension is known to be efficient, there are advances still to be made." | 2.38 | Current status and future goals of the pharmacologic reduction of portal hypertension. ( Lebrec, D, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 18 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| May, B | 4 |
| Hüppe, D | 2 |
| Jäger, D | 2 |
| Tromm, A | 2 |
| Barmeyer, J | 2 |
| Grosse-Heitmeyer, W | 1 |
| Huber, T | 1 |
| Ostrowski, J | 1 |
| Merino Ugarte, C | 1 |
| Wang, Y | 1 |
| Gu, C | 1 |
| Combis, JM | 2 |
| Vinel, JP | 3 |
| Badia, P | 1 |
| Barange, K | 1 |
| Payen, JL | 1 |
| Combis, F | 1 |
| Desmorat, H | 2 |
| Pascal, JP | 3 |
| García-Pagán, JC | 2 |
| Escorsell, A | 1 |
| Feu, F | 2 |
| Bandi, JC | 1 |
| Moitinho, E | 1 |
| Casado, M | 1 |
| Bosch, J | 2 |
| Rodés, J | 2 |
| Heinemann, A | 1 |
| Stauber, RE | 1 |
| Hori, N | 1 |
| Okanoue, T | 1 |
| Sawa, Y | 1 |
| Mori, T | 1 |
| Kashima, K | 1 |
| Patch, D | 1 |
| Burroughs, AK | 1 |
| Rodríguez-Pérez, F | 1 |
| Groszmann, RJ | 1 |
| Monnin, JL | 2 |
| Le Quellec, A | 1 |
| Taourel, P | 1 |
| Bruel, JM | 1 |
| Blanc, F | 1 |
| Michel, H | 1 |
| Ciurana, AJ | 1 |
| Lautt, WW | 1 |
| Ruiz del Arbol, L | 1 |
| Pizcueta, MP | 1 |
| Lebrec, D | 1 |
| Tunn, S | 1 |
| Calés, P | 1 |
5 reviews available for molsidomine and Cruveilhier-Baumgarten Syndrome
| Article | Year |
|---|---|
[Nitric oxide in gastroenterology].
Topics: Animals; Cells, Cultured; Chemical and Drug Induced Liver Injury; Digestive System; Digestive System | 1995 |
[Nitric oxide and hyperdynamic circulation in liver cirrhosis].
Topics: Animals; Humans; Hypertension, Portal; Liver Cirrhosis; Liver Cirrhosis, Experimental; Molsidomine; | 1995 |
Pharmacological treatment of portal hypertension.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Catheterization; Clinical Trials as Topic; Diu | 1995 |
Pharmacologic treatment of portal hypertension.
Topics: Adrenergic beta-Antagonists; Animals; Calcium Channel Blockers; Clonidine; Gastrointestinal Hemorrha | 1992 |
Current status and future goals of the pharmacologic reduction of portal hypertension.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Hemodynamics; Humans; Hypertension, Portal; | 1990 |
4 trials available for molsidomine and Cruveilhier-Baumgarten Syndrome
| Article | Year |
|---|---|
[Molsidomine in chronic heart failure with liver congestion--oral or intravenous therapy?].
Topics: Administration, Oral; Adult; Aged; Female; Heart Failure; Humans; Hypertension, Portal; Infusions, I | 1993 |
Propranolol plus molsidomine vs propranolol alone in the treatment of portal hypertension in patients with cirrhosis.
Topics: Adult; Blood Pressure; Drug Therapy, Combination; Female; Hemodynamics; Humans; Hypertension, Portal | 1996 |
[Evaluation of the effects of molsidomine and propranolol-molsidomine combination on portal hemodynamics by pulsed Doppler ultrasound].
Topics: Adult; Aged; Blood Flow Velocity; Drug Therapy, Combination; Female; Humans; Hypertension, Portal; L | 1992 |
Effects of molsidomine, a long acting venous dilator, on portal hypertension. A hemodynamic study in patients with cirrhosis.
Topics: Adult; Aged; Delayed-Action Preparations; Dose-Response Relationship, Drug; Female; Hemodynamics; He | 1991 |
9 other studies available for molsidomine and Cruveilhier-Baumgarten Syndrome
| Article | Year |
|---|---|
[Non-cardiac indications for administration of molsidomine. Introduction].
Topics: Esophageal Achalasia; Esophageal Spasm, Diffuse; Humans; Hypertension, Portal; Liver Cirrhosis; Mols | 1994 |
[Dose-dependent acute effect and long-term modification by molsidomine of portal and cardiac hemodynamics in patients with liver cirrhosis].
Topics: Adult; Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Esophageal and Gastric | 1994 |
[Non-cardiac indications for administration of molsidomine. Conclusions/perspectives].
Topics: Esophageal Motility Disorders; Humans; Hypertension, Portal; Liver Cirrhosis; Molsidomine; Portal Pr | 1994 |
Haemodynamic effects of molsidomine and propranolol in patients with cirrhosis.
Topics: Adrenergic beta-Antagonists; Drug Synergism; Drug Therapy, Combination; Female; Hemodynamics; Humans | 1996 |
Vasodilator responses to nitric oxide are enhanced in mesenteric arteries of portal hypertensive rats.
Topics: Acetylcholine; Animals; Dose-Response Relationship, Drug; Hypertension, Portal; Male; Mesenteric Art | 1996 |
Haemodynamic effects of combined treatment with molsidomine and propranolol on portal hypertension in conscious and unrestrained cirrhotic rats.
Topics: Animals; Drug Therapy, Combination; Hemodynamics; Hypertension, Portal; Liver Cirrhosis, Experimenta | 1996 |
The effects of linsidomine on portal hypertension.
Topics: Animals; Hypertension, Portal; Molsidomine; Portal System; Rats; Regional Blood Flow; Vascular Resis | 1992 |
[The effect of molsidomine on portal and cardiac hemodynamics in liver cirrhosis].
Topics: Adult; Aged; Female; Heart; Hemodynamics; Humans; Hypertension, Portal; Liver; Liver Cirrhosis; Live | 1991 |
Hemodynamic evaluation of molsidomine: a vasodilator with antianginal properties in patients with alcoholic cirrhosis.
Topics: Hemodynamics; Humans; Hypertension, Portal; Liver Cirrhosis, Alcoholic; Molsidomine; Splanchnic Circ | 1990 |